IGC Pharma Showcases Shannon Entropy Tau-PET Analysis on 1,570 Scans at Global Tau Conference
IGC Pharma will present a Tau-PET biomarker study at the 2026 Global Tau Conference analyzing 1,570 F-AV-1451 scans from 931 participants. The analysis found that among amyloid-positive APOE4 carriers, more focal tau spreading patterns correlated with worse cognitive outcomes and faster tau accumulation.
1. Conference Presentation
IGC Pharma will present its poster titled "Shannon Entropy of Tau-PET Spreading Patterns Predict Alzheimer's Disease Progression in Amyloid-Positive APOE4 Carriers" at the 2026 Global Tau Conference in Washington, D.C. on May 14-15. The session highlights advanced imaging analytics for tau pathology heterogeneity in Alzheimer's research.
2. Key Research Findings
The study leveraged 1,570 F-AV-1451 Tau-PET scans from 931 participants to quantify spatial heterogeneity in tau distribution using Shannon entropy. Results showed that focal tau spreading in amyloid-positive APOE4 carriers correlated with accelerated tau accumulation and worse cognitive outcomes over time.
3. Strategic Implications
These insights support IGC Pharma's strategy to integrate computational imaging analytics and AI into its Alzheimer’s pipeline, including the Phase 2 CALMA trial of IGC-AD1. Improved biomarker characterization may enhance patient stratification, disease monitoring, and future therapeutic development.